Findings of Research Misconduct, 67363-67364 [2013-26991]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 218 / Tuesday, November 12, 2013 / Notices
Bank of North Dakota, New Salem,
North Dakota.
Board of Governors of the Federal Reserve
System, November 6, 2013.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2013–26980 Filed 11–8–13; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
emcdonald on DSK67QTVN1PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than December 6,
2013.
A. Federal Reserve Bank of
Minneapolis (Jacqueline G. King,
Community Affairs Officer) 90
Hennepin Avenue, Minneapolis,
Minnesota 55480–0291:
1. Choice Financial Holdings, Inc.,
Grafton, North Dakota; to acquire 100
percent of the voting shares of Great
Plains National Bank, Belfield, North
Dakota.
In connection with this application,
Applicant also has applied to acquire 51
percent of the voting shares of Great
Plains National Insurance Agency, LLC,
LaMoure, North Dakota, and thereby
indirectly engage in general insurance
VerDate Mar<15>2010
17:41 Nov 08, 2013
Jkt 232001
agency activities in a community that
has a population not exceeding 5,000,
pursuant to section 225.28(b)(11)(iii)(A).
B. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Carroll County Bancshares, Inc.,
Carrollton, Missouri; to acquire up to
24.99 percent of the voting shares of
Adams Dairy Bancshares, Inc., and
thereby indirectly acquire voting shares
of Adams Dairy Bank, both in Blue
Springs, Missouri.
C. Federal Reserve Bank of Dallas (E.
Ann Worthy, Vice President) 2200
North Pearl Street, Dallas, Texas 75201–
2272:
1. FB Bancshares, Inc., Wichita Falls,
Texas; to merge with Byers Bancshares,
Inc., and thereby indirectly acquire First
National Bank, both in Byers, Texas.
Board of Governors of the Federal Reserve
System, November 6, 2013.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2013–26981 Filed 11–8–13; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Hao Wang, M.D., Ph.D., Western
University—Canada (formerly
University of Western Ontario): Based
on the report of an investigation
conducted by Western University—
Canada (WU) and ORI’s subsequent
oversight analysis, ORI found that Dr.
Hao Wang, former Associate Professor of
Surgery and Pathology, Schulich School
of Medicine and Dentistry, WU, engaged
in research misconduct in research
supported by National Institute of
Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH),
subaward 0016244 from Prime Award
U01 AI074676 to the University of
Pittsburgh.
ORI found that Respondent engaged
in research misconduct by falsifying
data that were included in:
• An abstract and poster presentation
for the 2011 American Transplant
Congress—Abstract [1537.5]: Wang, H.,
Baroja, M., Lan, Z., Arp, J., Lin, W.,
Relmann, K., Garcia, B., Jevnikar, A., &
SUMMARY:
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
67363
Rothstein, D. ‘‘Combination of Novel
Anti-CD45RB and Anti-CD40 Chimeric
Antibodies Proglons Renal Allograft
Survival in Cynomolgus Monkeys.’’
Specifically, ORI found that the
Respondent falsified the status of two
animals as successfully treated renal
allograft recipients in a 2011 American
Transplant Congress abstract and
meeting presentation and in false
representations to the project principal
investigators and colleagues.
Respondent falsely claimed long term
survival, normal serum creatinine
concentrations, and lack of adverse
effects in two Cynomolgus monkeys
treated with chimeric antibodies
following bilateral nephrectomies and
receipt of renal allografts, when in fact
the transplant surgery had failed and the
animals’ survival was due to a native
kidney that was left in place in each
animal. Respondent also falsified or
failed to correct known falsifications
(identifying the two monkeys as
transplant recipients) in numerous
clinical records, including anesthesia
records, progress, notes, treatment
records, and clinical laboratory reports.
It is expressly agreed that while
Respondent asserts that there are
extenuating factors for his actions,
Respondent agrees to enter into the
Agreement because contesting the
findings would cause him undue
financial hardship and stress, and
Respondent wishes to seek finality.
Respondent also claims that based on
the data obtained from the same
experimental group, the removal of
these two monkeys from the data would
not alter the scientific conclusion.
Dr. Wang has entered into a Voluntary
Settlement Agreement and has
voluntarily agreed for a period of three
(3) years, beginning on October 22,
2013:
(1) To have his research supervised;
Respondent agreed that prior to the
submission of an application for U.S.
Public Health Service (PHS) support for
a research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of his duties is
submitted to ORI for approval; the
supervision plan must be designed to
ensure the scientific integrity of
Respondent’s research contribution;
Respondent agreed that he shall not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed-upon supervision plan;
E:\FR\FM\12NON1.SGM
12NON1
67364
Federal Register / Vol. 78, No. 218 / Tuesday, November 12, 2013 / Notices
(2) that any institution employing him
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived, that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract, and that
the text in such submission is his own
or properly cites the source of copied
language and ideas; and
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
[FR Doc. 2013–26991 Filed 11–8–13; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
emcdonald on DSK67QTVN1PROD with NOTICES
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 10–1/8%, as fixed
by the Secretary of the Treasury, is
certified for the quarter ended
September 30, 2013. This rate is based
on the Interest Rates for Specific
Legislation, ‘‘National Health Services
17:41 Nov 08, 2013
Jkt 232001
Dated: October 18, 2013.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2013–26994 Filed 11–8–13; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
David E. Wright,
Director, Office of Research Integrity.
VerDate Mar<15>2010
Corps Scholarship Program (42 U.S.C.
254o(b)) and ‘‘National Research Service
Award Program (42 U.S.C.
288(c)(4)(B)).’’ This interest rate will be
applied to overdue debt until the
Department of Health and Human
Services publishes a revision.
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Endocrinologic
and Metabolic Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 12, 2013, from 8 a.m.
to 5 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993–
0002. Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Karen AbrahamBurrell, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email: EMDAC@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: The committee will discuss
the efficacy and safety of new drug
application (NDA) 202293, dapagliflozin
tablet, submitted by Bristol-Myers
Squibb. Dapagliflozin is a sodiumglucose cotransporter 2 inhibitor
developed as an adjunct to diet and
exercise to improve glycemic control in
adults with type 2 diabetes mellitus.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at: https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 27, 2013.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
November 19, 2013. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by November 20, 2013.
Persons attending FDA’s advisory
committee meetings are advised that the
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 78, Number 218 (Tuesday, November 12, 2013)]
[Notices]
[Pages 67363-67364]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-26991]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Hao Wang, M.D., Ph.D., Western University--Canada (formerly
University of Western Ontario): Based on the report of an investigation
conducted by Western University--Canada (WU) and ORI's subsequent
oversight analysis, ORI found that Dr. Hao Wang, former Associate
Professor of Surgery and Pathology, Schulich School of Medicine and
Dentistry, WU, engaged in research misconduct in research supported by
National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH), subaward 0016244 from Prime Award U01
AI074676 to the University of Pittsburgh.
ORI found that Respondent engaged in research misconduct by
falsifying data that were included in:
An abstract and poster presentation for the 2011 American
Transplant Congress--Abstract [1537.5]: Wang, H., Baroja, M., Lan, Z.,
Arp, J., Lin, W., Relmann, K., Garcia, B., Jevnikar, A., & Rothstein,
D. ``Combination of Novel Anti-CD45RB and Anti-CD40 Chimeric Antibodies
Proglons Renal Allograft Survival in Cynomolgus Monkeys.''
Specifically, ORI found that the Respondent falsified the status of
two animals as successfully treated renal allograft recipients in a
2011 American Transplant Congress abstract and meeting presentation and
in false representations to the project principal investigators and
colleagues. Respondent falsely claimed long term survival, normal serum
creatinine concentrations, and lack of adverse effects in two
Cynomolgus monkeys treated with chimeric antibodies following bilateral
nephrectomies and receipt of renal allografts, when in fact the
transplant surgery had failed and the animals' survival was due to a
native kidney that was left in place in each animal. Respondent also
falsified or failed to correct known falsifications (identifying the
two monkeys as transplant recipients) in numerous clinical records,
including anesthesia records, progress, notes, treatment records, and
clinical laboratory reports.
It is expressly agreed that while Respondent asserts that there are
extenuating factors for his actions, Respondent agrees to enter into
the Agreement because contesting the findings would cause him undue
financial hardship and stress, and Respondent wishes to seek finality.
Respondent also claims that based on the data obtained from the same
experimental group, the removal of these two monkeys from the data
would not alter the scientific conclusion.
Dr. Wang has entered into a Voluntary Settlement Agreement and has
voluntarily agreed for a period of three (3) years, beginning on
October 22, 2013:
(1) To have his research supervised; Respondent agreed that prior
to the submission of an application for U.S. Public Health Service
(PHS) support for a research project on which the Respondent's
participation is proposed and prior to Respondent's participation in
any capacity on PHS-supported research, Respondent shall ensure that a
plan for supervision of his duties is submitted to ORI for approval;
the supervision plan must be designed to ensure the scientific
integrity of Respondent's research contribution; Respondent agreed that
he shall not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI; Respondent agreed
to maintain responsibility for compliance with the agreed-upon
supervision plan;
[[Page 67364]]
(2) that any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived, that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract, and that the text in such
submission is his own or properly cites the source of copied language
and ideas; and
(3) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8800.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013-26991 Filed 11-8-13; 8:45 am]
BILLING CODE 4150-31-P
